One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis

被引：0
|
作者：
Alessandro Inno
Sandro Barni
Antonio Ghidini
Alberto Zaniboni
Fausto Petrelli
机构：
[1] IRCCS Ospedale Sacro Cuore Don Calabria,Oncology Unit, Cancer Care Center
[2] ASST Bergamo Ovest,Oncology Unit, Medical Sciences Department
[3] Casa di Cura Igea,Oncology Unit
[4] Casa di Cura Poliambulanza,Oncology Unit
来源：
Breast Cancer Research and Treatment | 2019年 / 173卷
关键词：
Breast cancer; Adjuvant; Trastuzumab; Duration; One year;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：247 / 254
页数：7
相关论文
共 50 条
  • [1] One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis
    Inno, Alessandro
    Barni, Sandro
    Ghidini, Antonio
    Zaniboni, Alberto
    Petrelli, Fausto
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (02) : 247 - 254
  • [2] Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    The, Due Ong
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (08) : 815 - 824
  • [3] Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis.
    Stewart, Paul
    Blanchette, Phillip S.
    Shah, Prakesh S.
    Ye, Xiang Y.
    Boldt, R. Gabriel
    Fernandes, Ricardo
    Vandenberg, Theodore A.
    Raphael, Jacques
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
    Wilson, Florence R.
    Coombes, Megan E.
    Brezden-Masley, Christine
    Yurchenko, Mariya
    Wylie, Quinlan
    Douma, Reuben
    Varu, Abhishek
    Hutton, Brian
    Skidmore, Becky
    Cameron, Chris
    [J]. SYSTEMATIC REVIEWS, 2018, 7
  • [5] Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
    Florence R. Wilson
    Megan E. Coombes
    Christine Brezden-Masley
    Mariya Yurchenko
    Quinlan Wylie
    Reuben Douma
    Abhishek Varu
    Brian Hutton
    Becky Skidmore
    Chris Cameron
    [J]. Systematic Reviews, 7
  • [6] Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
    Goldvaser, Hadar
    Korzets, Yasmin
    Shepshelovich, Daniel
    Yerushalmi, Rinat
    Sarfaty, Michal
    Ribnikar, Domen
    Thavendiranathan, Paaladinesh
    Amir, Eitan
    [J]. JNCI CANCER SPECTRUM, 2019, 3 (02)
  • [7] Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
    Wilson, Florence R.
    Coombes, Megan E.
    Wylie, Quinlan
    Yurchenko, Mariya
    Brezden-Masley, Christine
    Hutton, Brian
    Skidmore, Becky
    Cameron, Chris
    [J]. SYSTEMATIC REVIEWS, 2017, 6
  • [8] Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
    Florence R. Wilson
    Megan E. Coombes
    Quinlan Wylie
    Mariya Yurchenko
    Christine Brezden-Masley
    Brian Hutton
    Becky Skidmore
    Chris Cameron
    [J]. Systematic Reviews, 6
  • [9] Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
    Stewart, Paul
    Blanchette, Phillip
    Shah, Prakesh S.
    Ye, Xiang Y.
    Boldt, R. Gabriel
    Fernandes, Ricardo
    Vandenberg, Ted
    Raphael, Jacques
    [J]. BREAST, 2020, 54 : 203 - 210
  • [10] Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis
    Michelon, I. F.
    Vilbert, M. Silveira
    Marinho, A. D.
    Castro, C. E. D. R.
    Dacoregio, M. I.
    Stecca, C.
    Soares, L. R.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S357 - S357
12345